

## **NEUROENDOCRINE DISEASE ORIENTED GROUP**

CHELSEA HOTEL, TORONTO, ON ROOM: ROSSETTI ROOM

SATURDAY MAY 4<sup>TH</sup>, 2024 1:15 PM − 2:30 PM

CO-CHAIRS: DR SIMRON SINGH & DR TIM ASMIS SENIOR INVESTIGATOR: DR CHRIS O'CALLAGHAN

## CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

## Learning Objectives:

- To identify and address, through clinical and translational research, the disease burden associated with malignancies of the colon in Canada.
- To identify clinical trial research opportunities in malignancies of the colon within the Canadian Cancer Trials Group.
- To integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct as these relate to malignancies of the colon.
- To integrate and apply new clinical trial methodologies in malignancies of the colon in the Canadian Cancer Trials Group research agenda.
- To identify mentoring opportunities for new investigators with an interest in gastroenteropancreatic neuroendocrine malignancies

1:15 pm	Welcome	
1:20 pm	NE.1 (NETRETREAT): A Phase II RCT of Lu-177 DOTATATE Retreatment vs. Everolimus in metastatic/unresectable small bowel NET	Dr S Singh
1:35 pm	NE.2 (STOPNET-AGITG): A Randomized Study of Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid-Gut Neuroendocrine Tumours	Dr R Goodwin 8 Dr J Loree
1:50 pm	CORONET (AGITG): A Randomized Phase II/III study of peptide receptor radionuclide therapy (PRRT) and CAPTEM chemotherapy v PRRT alone in patients with pancreatic neuroendocrine neoplasms (pNENs) progressing on first line SSA therapy	Dr T Asmis
2:00 pm	ALPHA-NET: A comparative study of alpha peptide receptor radionuclide therapy (PRRT) versus 177Lu-DOTATATE for patients with advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs).	Dr T Krishnan
2:10 pm	COMMNETs – Commonwealth Neuroendocrine Tumour Collaboration Update	Dr T Asmis
2:20 pm	NCTN NET Task Force Update	Dr S Singh
2:30 pm	Meeting Adjourned	

&